YEREVAN (Noyan Tapan)–Chairwoman of the Pharmacological Commission–National Drug Agency–Professor Elmira Amroyan participated in the registration of Armenicum. She said in an interview that various groups were involved in the research work. The participation of these groups were required so that the research on the drug would stay in accordance with international standards.
The producer of the drug Armenicum corporation–research institutes including the Institute of Fine Organic Chemistry–Institute of Virology and Epidemiology and Institute of Oncology–and the National Drug Agency were all involved. The research work lasted over a year.
Experimen’s were first conducted on mice–rabbits–rats–dogs–and other experimental models. The initial data was to show that Armenicum was low-toxic.
Armenicum’s pharmacokinetics was studied in detail–which allowed the dosage and the treatment scheme to be correctly chosen.
Different indicators were used–including the content of CD-lymphocytes and polimerase chain reaction–for determining Armenicum’s effectiveness.
According to Amroyan–scientists have examined clinical data on over 150 patients. She did not rule out the possibility of newer better versions of the drug being discovered or the treatment scheme corrected.
She said that Armenicum’s future is beyond doubt. It should be noted that despite claims made by some mass media–none of the 150 AIDS patients who took a course of treatment displayed a negative effect of the treatment.